{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:13:51Z","timestamp":1790388831101,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T00:00:00Z","timestamp":1386806400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s40265-013-0155-7","type":"journal-article","created":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T14:02:31Z","timestamp":1386770551000},"page":"15-30","source":"Crossref","is-referenced-by-count":152,"title":["A Multi-Component Meningococcal Serogroup B Vaccine (4CMenB): The Clinical Development Program"],"prefix":"10.1007","volume":"74","author":[{"given":"Miguel","family":"O\u2019Ryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Stoddard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wassil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Dull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,12]]},"reference":[{"key":"155_CR1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1471-2334-10-175","volume":"10","author":"VN Racloz","year":"2010","unstructured":"Racloz VN, Luiz SJ. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis. 2010;10:175\u201383.","journal-title":"BMC Infect Dis"},{"key":"155_CR2","unstructured":"European Centre for Disease Prevention and Control. Surveillance of invasive bacterial diseases in Europe (2007); 2012. http:\/\/www.ecdc.europa.eu\/en\/publications\/Publications\/101011_SUR_Surveillance_of_invasive_bacterial_diseases_in_Europe_2007.pdf (Accessed 14 Aug 2012)."},{"key":"155_CR3","unstructured":"Centers for Disease Control and Prevention. Active bacterial core surveillance report, emerging infections program network, Neisseria meningitidis; 2008. http:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/mening08.html (Accessed 14 Aug 2012)."},{"key":"155_CR4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1586\/erv.13.30","volume":"12","author":"JA Bettinger","year":"2013","unstructured":"Bettinger JA, Deeks SL, Halperin SA, Tsang R, Scheifele DW. Controlling serogroup B invasive meningococcal disease: the Canadian perspective. Exp Rev Vacc. 2013;12:505\u201317.","journal-title":"Exp Rev Vacc"},{"issue":"Suppl 2","key":"155_CR5","doi-asserted-by":"crossref","first-page":"B26","DOI":"10.1016\/j.vaccine.2011.12.032","volume":"30","author":"SA Halperin","year":"2012","unstructured":"Halperin SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26\u201336.","journal-title":"Vaccine"},{"key":"155_CR6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1586\/14760584.2013.814879","volume":"12","author":"MAP S\u00e1fadi","year":"2013","unstructured":"S\u00e1fadi MAP, de los Monteros LE, L\u00f3pez EL, et al. The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative. Exp Rev Vaccines. 2013;12:903\u201315.","journal-title":"Exp Rev Vaccines"},{"key":"155_CR7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/erv.11.41","volume":"10","author":"WD Zollinger","year":"2011","unstructured":"Zollinger WD, Poolman JT, Maiden MC. Meningococcal serogroup B vaccines: will they live up to expectations? Expert Rev Vaccines. 2011;10:559\u201361.","journal-title":"Expert Rev Vaccines"},{"key":"155_CR8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1574-6976.2006.00057.x","volume":"31","author":"KA Jolley","year":"2007","unstructured":"Jolley KA, Brehony C, Maiden MC. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev. 2007;31:89\u201396.","journal-title":"FEMS Microbiol Rev"},{"key":"155_CR9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","volume":"338","author":"G Bjune","year":"1991","unstructured":"Bjune G, Hoiby EA, Gronnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338:1093\u20136.","journal-title":"Lancet"},{"issue":"Suppl 2","key":"155_CR10","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","volume":"27","author":"J Holst","year":"2009","unstructured":"Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27(Suppl 2):B3\u201312.","journal-title":"Vaccine"},{"key":"155_CR11","first-page":"48","volume":"122","author":"J O\u2019Hallahan","year":"2009","unstructured":"O\u2019Hallahan J, McNicholas A, Galloway Y, O\u2019Leary E, Roseveare C. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. N Z Med J. 2009;122:48\u201359.","journal-title":"N Z Med J"},{"key":"155_CR12","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/gbe\/evr119","volume":"3","author":"W Hao","year":"2011","unstructured":"Hao W, Ma JH, Warren K, et al. Extensive genomic variation within clonal complexes of Neisseria meningitidis. Genome Biol Evol. 2011;3:1406\u201318.","journal-title":"Genome Biol Evol"},{"key":"155_CR13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.4155\/cli.12.41","volume":"2","author":"J Wassil","year":"2012","unstructured":"Wassil J, McIntosh EDG, Serruto D, DeTora L, Broker M, Kimura A. The early clinical development of a multicomponent vaccine against meningococcal serogroup B. Clin Invest. 2012;2:503\u201317.","journal-title":"Clin Invest"},{"key":"155_CR14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1359-6446(03)02689-8","volume":"8","author":"M Mora","year":"2003","unstructured":"Mora M, Veggi D, Santini L, Pizza M, Rappuoli R. Reverse vaccinology. Drug Discov Today. 2003;8:459\u201364.","journal-title":"Drug Discov Today"},{"key":"155_CR15","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","volume":"103","author":"MM Giuliani","year":"2006","unstructured":"Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA. 2006;103:10834\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 2","key":"155_CR16","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1086\/648966","volume":"50","author":"DM Granoff","year":"2010","unstructured":"Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis. 2010;50(Suppl 2):S54\u201365.","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"155_CR17","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","volume":"27","author":"CE Frasch","year":"2009","unstructured":"Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009;27(suppl 2):B112\u20136.","journal-title":"Vaccine"},{"key":"155_CR18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","volume":"129","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969;129:1327\u201348.","journal-title":"J Exp Med"},{"key":"155_CR19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","volume":"129","author":"I Goldschneider","year":"1969","unstructured":"Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307\u201326.","journal-title":"J Exp Med"},{"key":"155_CR20","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","volume":"24","author":"R Borrow","year":"2006","unstructured":"Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005. Vaccine. 2006;24:5093\u2013107.","journal-title":"Vaccine"},{"key":"155_CR21","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","volume":"51","author":"J Findlow","year":"2010","unstructured":"Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51:1127\u201337.","journal-title":"Clin Infect Dis"},{"key":"155_CR22","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181faa6be","volume":"29","author":"MD Snape","year":"2010","unstructured":"Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29:e71\u20139.","journal-title":"Pediatr Infect Dis J"},{"key":"155_CR23","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/hv.7.6.15482","volume":"7","author":"D Toneatto","year":"2011","unstructured":"Toneatto D, Ismaili S, Ypma E, Vienken K, Oster P, Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin. 2011;7:646\u201353.","journal-title":"Hum Vaccin"},{"key":"155_CR24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"A Kimura","year":"2011","unstructured":"Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;18:483\u20136.","journal-title":"Clin Vaccine Immunol"},{"key":"155_CR25","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","volume":"185","author":"MD Snape","year":"2013","unstructured":"Snape MD, Saroey P, John TM, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ. 2013;185:E715\u201324.","journal-title":"CMAJ"},{"key":"155_CR26","first-page":"1116","volume":"32","author":"MD Snape","year":"2013","unstructured":"Snape MD, Philip J, John TM, et al. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. PIDJ. 2013;32:1116\u201321.","journal-title":"PIDJ"},{"key":"155_CR27","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","volume":"307","author":"N Gossger","year":"2012","unstructured":"Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307:573\u201382.","journal-title":"JAMA"},{"key":"155_CR28","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","volume":"381","author":"T Vesikari","year":"2013","unstructured":"Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381:825\u201335.","journal-title":"Lancet"},{"key":"155_CR29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","volume":"379","author":"ME Santolaya","year":"2012","unstructured":"Santolaya ME, O\u2019Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379:617\u201324.","journal-title":"Lancet"},{"key":"155_CR30","doi-asserted-by":"crossref","unstructured":"Santolaya ME, O\u2019Ryan ML, Valenzuela MT, et al. Persistence of antibodies in adolescents 18\u201324\u00a0months after immunization with one, two or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vacc Immunother. 2013;9. doi: 10.4161\/hv.25505 .","DOI":"10.4161\/hv.25505"},{"key":"155_CR31","unstructured":"Prymula R, Esposito S, Kittel C, et al. Prophylactic paracetamol in infants decreases fever following concomitant administration of an investigational meningococcal serogroup B vaccine with routine immunizations. 29th annual meeting of the European Society for Paediatric Infectious Diseases, The Hague; 2011."},{"key":"155_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/hv.23606","volume":"9","author":"J Holst","year":"2013","unstructured":"Holst J, Oster P, Arnold R, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future. Hum Vacc Immunother. 2013;9:1\u201313.","journal-title":"Hum Vacc Immunother"},{"key":"155_CR33","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","volume":"107","author":"J Donnelly","year":"2010","unstructured":"Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107:19490\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"155_CR34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","volume":"13","author":"U Vogel","year":"2013","unstructured":"Vogel U, Taha MK, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13:416\u201325.","journal-title":"Lancet Infect Dis"},{"key":"155_CR35","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","volume":"31","author":"G Frosi","year":"2013","unstructured":"Frosi G, Biolchi A, Lo Sapio M, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31:4968\u201374.","journal-title":"Vaccine"},{"key":"155_CR36","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1128\/CVI.00202-12","volume":"19","author":"BD Plikaytis","year":"2012","unstructured":"Plikaytis BD, Stella M, Boccadifuoco G, et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol. 2012;19:1609\u201317.","journal-title":"Clin Vaccine Immunol"},{"key":"155_CR37","unstructured":"Read RC, Baxter D, Chadwick DR, et al. Impact of a quadrivalent conjugate (MenACWY-CRM) or a serogroup B (4CMenB) meningococcal vaccine on meningococcal carriage in English university students. 31st meeting of the European Society for Paediatric Infectious Diseases, Milanl; 2013."},{"key":"155_CR38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.micpath.2013.02.003","volume":"57","author":"NM Caesar","year":"2013","unstructured":"Caesar NM, Myers KA, Fan X. Neisseria meningitidis serogroup B vaccine development. Micro Pathogen. 2013;57:33\u201340.","journal-title":"Micro Pathogen"},{"key":"155_CR39","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","volume":"12","author":"HS Marshall","year":"2013","unstructured":"Marshall HS, Richmond PC, Nissen MD, et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine. 2013;12:1569\u201375.","journal-title":"Vaccine"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0155-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0155-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0155-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T18:12:25Z","timestamp":1551204745000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0155-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["155"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0155-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,12]]}}}